State Street’s Aardvark Therapeutics AARD Stock Holding History

State Street’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$341K	Sell	59,273 -140,049	-70%	-$654K	﹤0.01%	3679
2026 Q1	$751K	Buy	199,322 +41,082	+26%	+$426K	﹤0.01%	3557
2025 Q4	$2.08M	Buy	158,240 +65,235	+70%	+$814K	﹤0.01%	3329
2025 Q3	$1.24M	Buy	93,005 +55,693	+149%	+$628K	﹤0.01%	3460
2025 Q2	$504K	Buy	+37,312	New	+$384K	﹤0.01%	3618

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

State Street's AARD Position: Q2 2026 in Review

State Street reduced its Aardvark Therapeutics (AARD) stake by 70% in Q2 2026, selling an estimated $654K and leaving 59,273 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

State Street first reported a position in AARD in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.08M in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

State Street held 59,273 shares of Aardvark Therapeutics worth $341K as of Q2 2026.
State Street sold 140,049 Aardvark Therapeutics shares in Q2 2026, an estimated $654K.
Aardvark Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3679 holding.
State Street first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 5 quarters since.
State Street's Aardvark Therapeutics position peaked at $2.08M in Q4 2025.
71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.